Tesamorelin — the stabilized GHRH analog, explained
Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoyl group that confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation. It is among the most thoroughly studied GHRH analogs in the clinical-research literature, with published Phase 2 and Phase 3 data on body-composition, visceral-adipose-tissue, and IGF-1-axis endpoints. This primer covers the molecule, the GHRH axis, the core clinical literature, and what distinguishes it from sermorelin.
The molecule. Tesamorelin has the 44-amino-acid sequence of native human GHRH (1-44) with an additional N-terminal modification: a trans-3-hexenoyl (hex-2-enoic acid) group attached to the Tyr1 α-amino group. Molecular weight is approximately 5,196 Da. The N-terminal modification was selected specifically to prevent DPP-IV cleavage, which in native GHRH occurs between residues 2 and 3 and limits the peptide's biological half-life to only a few minutes. The hexenoyl modification extends functional half-life to approximately 25-40 minutes in humans while preserving GHRH-receptor binding. The rest of the sequence is identical to native GHRH-1-44, which distinguishes tesamorelin from the shorter GHRH 1-29 fragment (sermorelin).
The GHRH axis. Growth-hormone-releasing hormone is synthesized in the arcuate nucleus of the hypothalamus and released in pulses into the hypothalamic-pituitary portal system, where it binds the GHRH receptor (GHRHR, a G-protein-coupled receptor) on pituitary somatotrophs. Receptor engagement triggers cAMP-mediated growth-hormone (GH) release. Circulating GH then stimulates hepatic and peripheral IGF-1 production, which mediates many of the downstream metabolic and tissue-level effects. The GHRH axis is pulsatile by design — somatostatin opposes GHRH to create the characteristic 3-hour release cycle. Tesamorelin's longer half-life increases pulse amplitude and duration without fundamentally disrupting pulsatility, which research protocols have positioned as its advantage over continuous GH administration.
Development history. Tesamorelin entered the clinical research literature in the late 2000s, with the original formulation studied in a specific metabolic-regulation research population under physician prescription. It was developed by Theratechnologies (Montreal, Canada). A reformulated stability-enhanced version followed in 2019. Tesamorelin is the most actively referenced acylated GHRH analog in current literature — sermorelin's active marketing authorization was withdrawn in 2008 — which makes tesamorelin the anchor reference compound for GHRH-analog research today.
Published literature — primary sources. The foundational Phase 2 trial is Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370 (doi: 10.1056/NEJMoa072375) — 412 participants, 26-week trial, established visceral-adipose-tissue reduction as the primary pharmacodynamic effect. The extended-dosing safety paper is Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728 (doi: 10.1097/QAD.0b013e32830a5058). The liver-fat study is Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014;312(4):380-389 (doi: 10.1001/jama.2014.8334) — established hepatic-lipid reduction as an additional pharmacodynamic endpoint.
Research applications. Beyond the original clinical-research population, published research has examined tesamorelin in (1) broader body-composition research — central-adiposity, hepatic-lipid, and post-menopausal metabolic research; (2) IGF-1-axis research — as a tool to produce sustained endogenous GH/IGF-1 elevation without exogenous GH administration, useful for receptor-signaling work and comparative pharmacology; (3) cognitive-aging research — the Friedman 2013 pilot (N Engl J Med-published for amnestic MCI) examined cognitive endpoints in older adults with cognitive complaints. The original clinical-research population evidence is the definitive research base; the other domains are smaller pilots or exploratory work.
Administration routes and dose ranges. The approved clinical dose is 2 mg subcutaneously daily. Research protocols have used 1 mg and 2 mg daily. Titration is not typically required; gastrointestinal tolerability is better than with amylin or GLP-1 analogs. Bedtime administration is often preferred to align with endogenous nocturnal GH-pulse patterns. Injection sites are rotated across the abdomen per standard subcutaneous-peptide handling. IGF-1 serum levels typically rise 2-4× baseline within the first 2 weeks of dosing at 2 mg daily — this is the principal pharmacodynamic marker for research-protocol monitoring.
Storage and handling. Tesamorelin is stable refrigerated (2-8 °C). Protect from light. Do not freeze. The original Egrifta formulation required reconstitution before each dose; Egrifta SV and research-format prefilled pens use a stability-enhanced solvent system that permits 28-day room-temperature in-use stability after first injection. The prefilled-pen format Vivaprime ships removes the vialing and reconstitution variability that historically complicated research-protocol standardization for daily-dosed peptides.
What the COA should say. A batch-specific COA for tesamorelin should include (1) identity by HPLC-MS matching the theoretical mass of approximately 5,196 Da, (2) purity by reverse-phase HPLC ≥ 98% with an impurity profile dominated by des-amido, oxidation, and deamidation variants, (3) endotoxin by LAL in EU/mg, (4) water content if lyophilized. The acylation at the N-terminus means the peptide is distinguishable from native GHRH by mass spectrometry (+96 Da shift vs. unmodified GHRH 1-44).
Research-use only. Vivaprime supplies tesamorelin as research reference material for qualified researchers engaged in in-vitro and research-context work. Clinical use of tesamorelin formulations is governed by physician prescription and is not the context in which research-grade material is supplied. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Purchasers affirm the research-use agreement at checkout. Related research primers: [sermorelin](/blog/sermorelin-research-primer), [ipamorelin and CJC-1295](/blog/ipamorelin-cjc-1295-research-primer), [IGF-1 LR3](/blog/igf-1-lr3-research-primer).